China Medical System Holdings Limited (the “Company”, together with its subsidiaries, the “Group”) is pleased to announce that the Group through its wholly-owned subsidiary entered into an Asset Transfer and License Agreement (the “Agreement”) with Acticor Biotech dated 31 July 2018. According to the Agreement, the Group acquired all assets (the “Assets”) related to Acticor Biotech’s product ACT017 and any follow-up products developed on the basis of the same compound of ACT017 (the “Products”) in China (including Hong Kong Special Administrative Region, Macao Special Administrative Region and Taiwan), Singapore, Philippines, Republic of Korea, Malaysia and other designated Asian countries (excluding Japan, India and Western Asia countries) (the “Territory”), and the Assets include without limitation all the know-how, intellectual property or the right of application for the intellectual property, necessary regulatory approvals, documents, dossiers, data or information exclusive for the Territory and other rights as necessarily required to develop, register, manufacture and commercialize the Products in the Territory. In addition, the Group also acquired all the necessary licenses related to the transaction under the Agreement.
ACT017 is a high affinity humanized antibody fragment (Fab) directed against the platelet glycoprotein VI (GPVI) and is being developed for the treatment of the acute phase of ischemic stroke, as an add-on therapy on top of thrombolysis and/or thrombectomy, or as a standalone treatment for patients who are not eligible to thrombolysis. ACT017 works quickly via IV administration, and the possibility of drug accumulation is relatively small for a short half-life. The substance patent of ACT017 has entered into the Chinese national phase via PCT international application and published, which will expire in 2036, if granted. ACT017 has completed the European Phase I clinical trial and plans to launch a European Phase Ib/II clinical trial.
Acticor Biotech, a France clinical stage biotechnology company, is a spin-off company from INSERM (French National Institute of Health and Medical Research) founded in November 2013, dedicated to developing an innovative treatment in the therapy of acute thrombotic diseases, including ischemic stroke and pulmonary embolism. Acticor Biotech is built upon the expertise and the results of researches conducted by the founders: Dr. Martine Jandrot-Perrus at INSERM Paris and Professor Philippe Billiald at Paris-Sud University.
The Group believes that the Products will have broad market prospects after being commercialized in the Territory. Through this cooperation, the Group will accelerate the pace of introducing patented innovative products to accumulate rich pipeline products for future development
